Bioasis Technologies Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BTI.V research report →
Companywww.bioasis.us
Bioasis Technologies Inc. , a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases.
- CEO
- Deborah Ann Rathjen FTSE,
- IPO
- 2008
- HQ
- New Haven, CT, US
Price Chart
Valuation
- Market Cap
- $397.07K
- P/E
- -0.12
- P/S
- 10.53
- P/B
- -0.19
- EV/EBITDA
- -0.16
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -45.57%
- Op Margin
- -12956.07%
- Net Margin
- -7846.50%
- ROE
- 392.02%
- ROIC
- -494.10%
Growth & Income
- Revenue
- $37.73K · -99.07%
- Net Income
- $-2,960,092 · -523.83%
- EPS
- $-0.04 · -501.96%
- Op Income
- $-4,887,678
- FCF YoY
- -305.22%
Performance & Tape
- 52W High
- $0.01
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- 0.51
- Avg Volume
- 0
Get TickerSpark's AI analysis on BTI.V
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BTI.V Coverage
We haven't published any research on BTI.V yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BTI.V Report →